The role of endoscopy in the prevention of esophagogastric cancer

Endoscopy

Volumn 31, Issue 2, 1999, Pages 180-199

  Lambert, R ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DIGESTIVE TRACT ENDOSCOPY; DYSPEPSIA; ESOPHAGUS CANCER; GASTROESOPHAGEAL REFLUX; HUMAN; LOWER ESOPHAGUS SPHINCTER; MORBIDITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; STOMACH CANCER;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; ENDOSCOPY, DIGESTIVE SYSTEM; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; GASTROESOPHAGEAL REFLUX; HUMANS; INCIDENCE; MASS SCREENING; PREVALENCE; STOMACH NEOPLASMS;

EID: 0033036409     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-1999-13669     Document Type: Review

References (95)

1. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33: 1075-107
2. Ferlay J, Black RJ, Pisani P, et al. EUCAN 90. Cancer in the European Union: IARC cancer data base. 1. Lyon: International Agency for Research on Cancer Press, 1996
3. Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents. Lyon International Agency for Research on Cancer Press (IARC publication no. 143; distributed by Oxford University Press), 1997
4. Coleman MP, Esteve J, Damiecki P, et al. Trends in cancer incidence and mortality. Lyon International Agency for Research on Cancer Press (IARC publication no. 121; distributed by Oxford University Press), 1993
5. Zalonski W, Samans M, Tyczynski NJ, Boyle P. Atlas of cancer mortality in Central Europe.Lyon International Agency for Research on Cancer Press (IARC publication no. 134; distributed by Oxford University Press), 1996
6. Fujimoto I, Hanai A, Hiyama T, et al. Cancer incidence and mortality in Osaka, 1963-1989. Tokyo Shinohara, 1993
7. Daly JM, Karnell LH, Menck HR. National Cancer database report on esophageal carcinoma. Cancer 1996; 78: 1820-8
8. Hansen S, Wiig JN, Giercksky KE, Tretli S. Esophageal and gastric carcinoma in Norway, 1958-1992: incidence, time trend variability according to morphological subtypes and organ subsites. Int J Cancer 1997; 71: 340-4
9. Powell J, McConkey CC. The raising trend in esophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev 1992; 1: 265-9
10. Pera M, Cameron AZJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510-3
11. Cameron AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 1995; 109: 1541-6
12. Cameron AJ. Epidemiology of columnar lined esophagus and adenocarcinoma. Gastroenterol Clin N Am 1997; 26: 487-94
13. Reed P, Johnston BJ. The changing incidence of oesophageal cancer. Endoscopy 1993; 25: 606-8
14. Reid BJ, Barrett MT, Galipeau PC, et al. Barrett's esophagus: ordering the events that lead to cancer. Eur J Cancer Prev 1996; 5 (Suppl. 2): 57-65
15. SEER. Incidence Public Use Database. 1973-1995. National Cancer Institute. Bethesda, Md, USA. National Institute of health. 1998
16. Levine DS. Management of dysplasia in the columnar-lined esophagus. Gastroenterol Clin N Am 1997; 26: 613-35
17. Schlemper RJ, Itabashi M, Kato Y, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and Western pathologists. Lancet 1997; 349: 1725-9
18. Oshima A. Secondary prevention: screening methods in high incidence areas. In: Sugimura T, Sasako M (editors). Gastric cancer. Oxford Oxford University Press, 1997: 199-212
19. Hanai A, Tsukuma H, Hiyama T, Fujimoto I. Survival of patients with stomach cancer: results from population-based cancer registries. In: Sugimura T, Sasako M (editors). Gastric cancer. Oxford: Oxford University Press, 1997: 1-30
20. Pisani P, Parkin DM. Screening for gastric cancer. In: Miller AB (editor). Advances in cancer screening. Boston: Kluwer, 1996: 113-9
21. Berrino F, Sant M, Verdecchia A, Capocaccia R. Survival of cancer patients in Europe: the Europe study. Lyon IARC Press (IARC publication no. 132, distributed by Oxford University Press), 1995
22. Hosokawa O, Tsuda S, Kidani E, et al. Diagnosis of gastric cancer up to three years after negative upper GI endoscopy. Endoscopy 1998; 30: 669-74
23. Lambert R. Endoscopic treatment of esophagogastric tumors. Endoscopy 1988; 30: 80-93
24. Sue-Ling HM, Johnston D, Martin IG, et al. Gastric cancer: a curable disease in Britain. Br Med J 1993; 307: 591-6
25. Kodama M, Kagewara T. Treatment of superficial cancer of the esophagus: a summary of responses to a questionnaire on superficial cancer of the esophagus in Japan. Surgery 1998; 123: 432-9
26. Ponec RJ, Kimmey MB. Endoscopic therapy of esophageal cancer. Surg Clin N Am 1997; 77: 1197-217
27. Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259-68
28. Holtmann G, Goebell H, Talley NJ. Dyspepsia in consulters and nonconsulters: prevalence, healthcare-seeking behaviour and risk factors. Eur J Gastroenterol Hepatol 1994; 6: 917-24
29. Drossmann DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders: prevalence, sociodemography and health impact. Dig Dis Sci 1993; 38: 1569-80
30. Tebaldi K, Heading RC. Clinical economics review: functional non-ulcer dyspepsia. Aliment Pharmacol Ther 1998; 12: 11-9
31. Talley NJ, Hunt RH. What role does Helicobacter pylori play in dyspepsia and non-ulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology 1997; 113 (Suppl. 6): 67-77
32. Talley NJ, Weaver AL, Zinsmeister AR, et al. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemol 1992; 136: 165-77
33. Johannessen T, Petersen H, Kleveland PM, et al. The predictive value of history in dyspepsia. Scand J Gastroenterol 1990; 25: 689-97
34. Bytzer P, Moller-Hansen J, Schaffalitzky de Muckadell OB, et al. Predicting endoscopic diagnosis in the dyspeptic patient: the value of clinical judgement. Eur J Gastroenterol Hepatol 1996; 8: 359-63
35. Bytzer P, Moller-Hansen J, Havelund T, et al. Predicting endoscopic diagnosis in the dyspeptic patient: the value of predictive score models. Scand J Gastroenterol 1997; 32: 118-25
36. Gonvers JJ, Burnand B, Froehlich F, et al. Appropriateness and diagnostic yield of upper gastrointestinal endoscopy in an open access endoscopy unit. Endoscopy 1996; 28: 661-6
37. Adang RP, Visman JF, Talmon JL, et al. Appropriateness of indications for diagnostic upper gastrointestinal endoscopy: association with relevant endoscopic disease. Gastrointest Endose 1995; 42: 390-7
38. Kahn KL, Kosecoff J, Chassin MR. The use and misuse of upper gastrointestinal endoscopy. Ann Intern Med 1988; 109: 664-70
39. Kahn KL, Park RE, Vennes J, et al. Health and Public Policy Committee. Assigning appropriateness ratings for diagnostic upper gastrointestinal endoscopy using two different approaches. Med Care 1992; 30: 1016-28
40. Talley NJ, Silverstein MD, Agreus L, et al. AGA technical review: evaluation of dyspepsia. Gastroenterology 1998; 114: 582-95
41. Mahajan RJ, Marshall JB. Prevalence of open access gastrointestinal endoscopy in the United States. Gastrointest Endosc 1997; 46: 21-6
42. Mahajan RJ, Barthel JS, Marshall JB. Appropriateness of referrals for open access endoscopy: how do physicians in different medical specialties do? Arch Intern Med 1996; 156: 2065-9
43. Minoli G, Prada A, Gambetta G, et al. The ASGE guidelines for the appropriate use of upper gastrointestinal endoscopy in an open access system. Gastrointest Endosc 1995; 42: 387-9
44. Thompson WG. Dyspepsia: is a trial of therapy appropriate? Can Med Assoc J 1995; 153: 293-5
45. Kahn KL, Creenfield S. Endoscopy in the evaluation of dyspepsia. Ann Intern Med 1985; 102: 266-9
46. Axon ATR. Chronic dyspepsia: who needs endoscopy? Gastroenterology 1998; 112: 1376-80
47. American Gastroenterological Association. Medical position statement: evaluation of dyspepsia. Gastroenterology 1998; 114: 579-81
48. Sonnenberg A, Townsend WF, Muller AD. Evaluation of dyspepsia and functional gastrointestinal disorders: a cost-benefit analysis of different approaches. Eur J Gastroenterol Hepatol 1995; 7: 655-9
49. Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med 1995; 123: 260-8
50. Ofmann JJ, Etachson J, Fullerton S, et al. Management strategies for Helicobacter pylori seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med 1997; 126: 280-91
51. Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology 1996; 110: 72-83
52. 2-receptor antagonists in patients with dyspepsia and heartburn: a cost comparison. Med J Aust 1993; 155: 20-6
53. Zuccaro G, Provencher K. Does an open access system properly utilize endoscopic resources? Gastrointest Endosc 1997; 46: 15-20
54. 2-blocker therapy or prompt endoscopy in management of dyspepsia? Lancet 1994; 343: 811-81
55. Froehlich F, Burnand B, Pache I, et al. Overuse of upper gastrointestinal endoscopy in a country with open access endoscopy: a prospective study in primary care. Gastrointest Endosc 1997; 45: 13-9
56. Froehlich F, Pache I, Burnand B, et al. Underutilization of upper gastrointestinal endoscopy. Gastroenterology 1997; 112: 690-7
57. Hungin APS, Thomas PR, Bramble MG, et al. What happens to patients following open access gastroscopy? An outcome study from general practice. Br J Gen Pract 1994; 44: 519-21
58. Quine MA, Bell GD, McCloy RIF, et al. Appropriate use of upper gastrointestinal endoscopy: a prospective audit. Gut 1994; 35: 1209-14
59. Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56
60. Loof L, Gotell P, Elfberg B. The incidence of reflux esophagitis: a study of endoscopy reports from a defined catchment area in Sweden. Scand J Gastroenterol 1993; 28: 113-8
61. Petersen H. The prevalence of gastro-esophageal reflux disease. Scand J Gastroenterol 1995; 30 (Suppl. 211): 5-6
62. Small PK, Loudon MA, Waldron B, et al. Importance of reflux symptoms in functional dyspepsia. Gut 1995; 36: 189-92
63. Wienbeck M, Barnert J. Epidemiology of reflux disease and reflux esophagitis. Scand J Gastroenterol 1989; 245 (Suppl. 156): 7-13
64. Berstad A, Hatlebakk JG. The predictive value of symptoms in gastro-oesophageal reflux disease. Scand J Gastroenterol 1995; 30 (Suppl. 21): 1-4
65. Rune SJ. Heartburn and dyspepsia: the utility of symptom analysis. Aliment Pharmacol Ther 1997; 11 (Suppl. 2): 9-12
66. Helfand M, Liebermann DA, Oehlke M. Community-based research-a framework for problem formulation: the case of upper endoscopy for gastro-oesophageal reflux disease. Med Decis Making 1997; 17: 315-23
67. Talley NJ. Dyspepsia. Clinical Gastroenterology 1998; 12: 3, 418-624
68. McDougall NI, Johnston BT, Kee F, et al. Natural history of reflux esophagitis: a 10-year follow-up of its effect on patient symptomatology and quality of life. Gut 1996; 38: 481-6
69. Sontag SJ. Rolling review: gastroesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 293-312
70. Labenz J, Blum AL, Bayerdorffer E, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442-7
71. El Omar EM, Oien K, El Nujumi A. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15-24
72. Kuipers EJ, Lee A, Klinkenberg-Knoll EC, Meuwissen SG. The development of atrophic gastritis: Helicobacter pylori and the effect of acid-suppressive therapy. Aliment Pharmacol Ther 1995; 9: 331-40
73. Kuipers EJ, Lundell L, Klinkenberg K, et al. Atrophic esophagitis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22
74. Smout AJPM. Endoscopy negative acid reflux disease. Aliment Pharmacol Ther 1997; 11 (Suppl. 2): 81-5
75. Bytzer P, Havelund T, Moller-Hansen J. Interobserver variation in the endoscopic diagnosis of reflux esophagitis. Scand J Gastroenterol 1993; 28: 119-25
76. Wilkinson SP. The limits of endoscopy in the diagnosis of oesophagitis, gastritis and duodenitis. Aliment Pharmacol Ther 1997; 11 (Suppl. 2): 13-7
77. Dent J. Management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1997; 11 (Suppl. 2): 99-105
78. Devault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Arch Intern Med 1995; 155: 2165-73
79. Lundell L. New Information relevant to long-term management of endoscopy-negative reflux disease. Aliment Pharmacol Ther 1997; 11 (Suppl. 2): 93-8
80. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10
81. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastrooesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 965-73
82. Glise H, Wiklund I. Measurement of the impact of heartburn and dyspepsia on the quality of life. Aliment Pharmacol Ther 1997; 11 (Suppl. 2): 73-7
83. Heudebert GR, Marks R, Wilcox CM, Centor RM. Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. Gastroenterology 1997; 112: 1078-86
84. Lind T, Havelund T, Carlsson R. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 327: 974-9
85. Spechler SJ, Zeroogian JM, Antonioli DA, et al. Prevalence of metaplasia at the gastrooesophageal junction. Lancet 1994; 344: 1533-6
86. Nandurkar S, Talley NJ, Martin CJ, et al. Short-segment Barrett's oesophagus: prevalence, diagnosis and associations. Gut 1997; 40: 710-5
87. Spechler SJ. Esophageal columnar metaplasia (Barrett's esophagus). Gastroenterol Endosc Clin N Am 1997; 7: 1-18
88. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus: comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99: 918-22
89. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia and Norman Barrett. Gastroenterology 1996; 110: 616-21
90. Winters C, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus: a prevalent occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 118-22
91. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. Am J Gastroenterol 1997; 92: 1293-7
92. Falk GW, Richter JE. Reflux disease and Barrett's esophagus. Endoscopy 1998; 30: 61-72
93. Ruol A, Merigliano S, Baldan N, et al. Prevalence, management and outcome of early adenocarcinoma (pT1) of the esophagogastric junction: comparison between early cancer in Barrett's esophagus (type I) and early cancer of the cardia (type II). Dis Esophagus 1997; 10: 190-5
94. Van der Burgh A, Hop WC, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996; 39: 5-8
95. Tytgat GNJ. Does endoscopic surveillance in esophageal columnar metaplasia (Barrett's esophagus) have any value? Endoscopy 1993; 27: 19-26